---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-011411"
form_type: "8-K"
ticker: "ADGM"
cik: "0002006986"
company_name: "Adagio Medical Holdings, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T14:03:28.896141+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Adagio Medical Q2 2025 net loss $3.9M; FULCRUM-VT enrollment at 85%

## Summary
- Net loss narrowed to $3.9M ($0.26 basic EPS) from $5.7M in Q2 2024; revenue figure not disclosed.
- Cash and equivalents of $8.2M as of June 30; cash burn reduced via corporate prioritization.
- FULCRUM-VT pivotal study enrollment surpassed 85% of 206 patients; completion expected H2 2025.
- First-in-human PARALELL PFCA results published in Journal of Cardiovascular Electrophysiology.
- R&D expense down 31% to $2.0M; SG&A down 29% to $2.4M year-over-year.

## SEC filing metadata
- accession: 0001558370-25-011411
- form_type: 8-K
- ticker: ADGM
- cik: 0002006986
- company_name: Adagio Medical Holdings, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2006986/000155837025011411/0001558370-25-011411-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2006986/000155837025011411/adgm-20250813x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-011411
- JSON: https://secwatch.observer/filing/0001558370-25-011411.json
- Plain text: https://secwatch.observer/filing/0001558370-25-011411.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.